5-MeO-DiPT
5-MeO-DiPT is a synthetic psychedelic of the tryptamine class1 first described by Alexander Shulgin in 19802. It is considered an atypical psychedelic, characterized by prominent stimulating and mildly entactogenic effects rather than typical visual distortions. The compound is particularly noted for producing strong tactile and sexual enhancement alongside auditory distortions similar to those of the related compound DiPT. Higher doses are frequently reported to produce an unpleasant body load.
Contents
Dosage & Duration
Dosage
Users report steep dosage curve. Start lower than expected.
Duration
Subjective Effects
5-MeO-DiPT occupies an unusual position among the tryptamines, producing a primarily body-centered experience with stimulant- and entactogen-like qualities rather than a classically visionary psychedelic state. The experience is dominated by a strong bodily energy or buzzing sensation, pronounced tactile and sexual enhancement, and only light perceptual alterations, with full effects arriving within roughly the first hour of onset. Effects are sometimes described as wave-like, ebbing and flowing in intensity, and reports of deeply engrossing visions or hallucinations are notably absent even at strong doses.
Physical
The body load is prominent and polarizing: a buzzing muscular energy accompanied by stimulation, sweating, muscle tension, and jaw clenching. Gastrointestinal effects are characteristic, including stomach discomfort, gas, markedly increased peristalsis, and diarrhea, and many users find it difficult to sleep for 4-12 hours after the peak.
Stimulation
The substance is distinctly stimulating in both body and mind, producing a buzzing muscular energy that some users enjoy and others find aversive; restlessness is common.
Uncomfortable
Gastrointestinal disturbance is a well-known signature of the substance, though it does not affect all users.
Cognitive
The headspace tends toward euphoria, emotional openness, and an outgoing, socially oriented mental activation rather than deep introspection or intuitive insight. Time frequently feels slowed, particularly during the come-up, and some users experience confusion, ego softening, or an anxious edge to the stimulation.
Disruptive
Emotional
The emotional tone is generally positive and opening, though the stimulation can carry an anxious or unnerving edge, especially when the body load becomes uncomfortable.
Visual
Visual effects are light relative to most psychedelic tryptamines, consisting mainly of subtle enhancements and distortions; closed-eye imagery appears mainly at higher doses, and fully formed hallucinations are not reported.
Distortions
Auditory
Auditory effects lean toward distortion rather than enhancement; music can sound strange, fake, or shifted in a manner reminiscent of DiPT, and many users find music less engaging than usual.
Tactile
Tactile enhancement is a defining feature of the substance, with the entire body feeling alive and alert; touch takes on a strongly sensual or erotic quality for many users.
Olfactory
Gustatory
Reagent Testing
Loading reagent data
Pharmacology
Pharmacodynamics
5-MeO-DiPT acts as a non-selective serotonin receptor agonist with activity at the 5-HT1A, 5-HT1B, 5-HT1D, 5-HT2A, 5-HT2B, and 5-HT2C receptors.3 Binding affinity is strongest at the 5-HT1A receptor, reported as 2-fold to 161-fold greater than at 5-HT2A across studies. In functional assays, however, activation potency is similar at 5-HT1A and 5-HT2A, with several-fold lower potency at 5-HT2C. The psychedelic effects are thought to result primarily from 5-HT2A receptor agonism.34 5-MeO-DiPT also acts as a serotonin reuptake inhibitor with variable reported potency, while showing no significant dopamine or norepinephrine reuptake inhibition and no monoamine releasing activity.5 In rodent models, the compound elevates brain serotonin levels (presumably via serotonin reuptake inhibition) and may also increase dopamine levels through an unknown mechanism, though findings on the latter are mixed.36
Pharmacokinetics
The pharmacokinetics and metabolism of 5-MeO-DiPT have been studied, but detailed pharmacokinetic parameters are not well-established.7
Dangerous
Highest riskThese combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
Unsafe
AvoidThere is considerable risk of physical harm when taking these combinations, they should be avoided where possible.
Caution
Use cautionThese combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.
Harm Potential
Addiction & Dependence
Psychological
Extremely LowLike other serotonergic psychedelics, 5-MeO-DiPT is not habit-forming.9 Evidence remains limited, but related tryptamines are not typically described as addictive or prone to compulsive use.
Toxicity
Serotonergic neurotoxicity has been demonstrated in rodent models, with cognitive deficits in spatial navigation, cognitive flexibility, and attention observed following adolescent exposure; effects are described as less severe than those of MDMA, and human relevance remains unclear.10
Rhabdomyolysis and acute renal failure have been reported in the context of overdose; this appears to be an acute toxicity concern rather than a chronic use issue.12
Psychosis Risk
One report describes a prolonged delusional state associated with 5-MeO-DiPT.13 Those whose family history includes schizophrenia or early-onset mental illness should be cautious, because psychedelics may trigger latent psychological or mental problems.
History & Culture
5-MeO-DiPT was first synthesized and tested by American chemist Alexander Shulgin2, who conducted the initial human trials of the compound in 1975. Shulgin subsequently co-authored a paper with M. F. Carter detailing the synthesis and human psychopharmacology of both 5-MeO-DiPT…
Legality
By Country
References
Source Pages
Citations
- Drug Enforcement Administration, Diversion Control Division. (October 2025). 5-METHOXY-N,N-DIISOPROPYLTRYPTAMINE (Street Names: Foxy, or Foxy methoxy). U.S. Drug Enforcement Administration. https://www.deadiversion.usdoj.gov/drug_chem_info/5meodipt.pdf12
- (1980). N, N-Diisopropyltryptamine (DIPT) and 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT). Two orally active tryptamine analogs with CNS activity. Commun Psychopharmacol, 4(5), 363–369. https://bitnest.netfirms.com/external/Commun.Psychopharmacol/4.5.363123
- (November 2016). Neurotoxic Effects of 5-MeO-DIPT: A Psychoactive Tryptamine Derivative in Rats. Neurotox Res, 30(4), 606–619. https://doi.org/10.1007/s12640-016-9654-012345678910
- (September 2025). Effects of three tryptamines: alpha-methyltryptamine, 5-methoxy-alpha-methyltryptamine, and 5-methoxy- N , N -diisopropyltryptamine on acute toxicity, locomotor activity, and hallucinogenic behavior in mice. Behav Pharmacol, 36(6), 429–437. https://doi.org/10.1097/fbp.00000000000008411
- (October 2014). Interaction of psychoactive tryptamines with biogenic amine transporters and serotonin receptor subtypes. Psychopharmacology (Berl), 231(21), 4135–4144. https://doi.org/10.1007/s00213-014-3557-7123
- (March 2021). Dual actions of 5-MeO-DIPT at the serotonin transporter and serotonin 5-HT1A receptor in the mouse striatum and prefrontal cortex. Neuropsychopharmacol Rep, 41(1), 91–101. https://doi.org/10.1002/npr2.121611
- (April 2006). Oxidative metabolism of 5-methoxy-N,N-diisopropyltryptamine (Foxy) by human liver microsomes and recombinant cytochrome P450 enzymes. Biochem Pharmacol, 71(9), 1377–1385. https://doi.org/10.1016/j.bcp.2006.01.0151
- (2015-02-10). 5-MeO-DiPT Basics. Erowid. https://erowid.org/chemicals/5meo_dipt/5meo_dipt_basics.shtml123
- (April 2016). Psychedelics. Pharmacol Rev, 68(2), 264–355. https://doi.org/10.1124/pr.115.01147812
- (May 2011). 5-methoxy-N,N-di(iso)propyltryptamine hydrochloride (Foxy)-induced cognitive deficits in rat after exposure in adolescence. Physiol Behav, 103(2), 203–209. https://doi.org/10.1016/j.physbeh.2011.01.0211
- (2019). Effects of exposure to 5-MeO-DIPT during adolescence on brain neurotransmission and neurotoxicity in adult rats. Forensic Toxicol, 37(1), 45–58. https://doi.org/10.1007/s11419-018-0433-x1
- (April 2006). Rhabdomyolysis after ingestion of "foxy," a hallucinogenic tryptamine derivative. Mayo Clin Proc, 81(4), 550–551. https://doi.org/10.4065/81.4.5501
- (April 2013). Prolonged delusional state triggered by repeated ingestion of aromatic liquid in a past 5-methoxy-N, N-diisopropyltryptamine abuser. Addict Sci Clin Pract, 8(1). https://doi.org/10.1186/1940-0640-8-91
- Alexander Shulgin, & Ann Shulgin. (1997). TiHKAL: The Continuation. Transform Press. https://www.erowid.org/library/books_online/tihkal/tihkal37.shtml12
- (December 2005). Foxy methoxy: a new drug of abuse. J Med Toxicol, 1(1), 22–25. https://doi.org/10.1007/bf0316090112
- (December 2018). Correlates of HIV infection among transgender women in two Chinese cities. Infect Dis Poverty, 7(1). https://doi.org/10.1186/s40249-018-0508-21
- (2019). Gesetz über den Verkehr mit Betäubungsmitteln: Anlage I. https://www.gesetze-im-internet.de/btmg_1981/anlage_i.html1
- UK Legislation. (n.d.). Misuse of Drugs Act 1971, Schedule 2, Part I. legislation.gov.uk. https://www.legislation.gov.uk/ukpga/1971/38/schedule/2/part/I1
- Department of Justice Drug Enforcement Administration (Dea). (April 2003). Schedules of controlled substances: temporary placement of alpha-methyltryptamine and 5-methoxy-N,N-diisopropyltryptamine into Schedule I. Final rule. Fed Regist, 68(65), 16427–16430. https://pubmed.ncbi.nlm.nih.gov/12678045/1
- Department of Justice Drug Enforcement Administration (Dea). (September 2004). Schedules of controlled substances: placement of alpha-methyltryptamine and 5-methoxy-N,N-diisopropyltryptamine into schedule I of the Controlled Substances Act. Final rule. Fed Regist, 69(188), 58950–58953. https://pubmed.ncbi.nlm.nih.gov/15455477/1
- US Government Publishing Office. (2023). 21 CFR 1308.11 -- Schedule I. Code of Federal Regulations, Title 21, Volume 9. https://www.govinfo.gov/content/pkg/CFR-2023-title21-vol9/xml/CFR-2023-title21-vol9-sec1308-11.xml1
- US Government Publishing Office. (2023). 21 CFR 1301.11 -- Persons required to register. Code of Federal Regulations, Title 21, Volume 9. https://www.govinfo.gov/content/pkg/CFR-2023-title21-vol9/xml/CFR-2023-title21-vol9-sec1301-11.xml1
Further Reading
Automated synthesisInformation aggregated and synthesized using an autonomous workflow built by Josie Kins.
Suggest an edit
Spotted a mistake, an outdated claim, or something missing from the 5-MeO-DiPT article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.